Novo Nordisk expands AI drug discovery as patent expiry nears | TrendHub AI
Novo Nordisk expands AI drug discovery as patent expiry nears
AI Healthcare
Novo Nordisk expands AI drug discovery as patent expiry nears
AxiosSep 28, 2026
Novo Nordisk is increasingly using AI to develop new drugs as patents for its GLP-1-based medications near expiration.
Novo Nordisk, recently rebranded simply as Novo, is increasingly leveraging artificial intelligence (AI) to develop new pharmaceuticals. As the maker of leading weight-loss drugs Ozempic and Wegovy, the company is focusing on AI-driven drug discovery to expand and diversify its portfolio, particularly with the looming expiration of patents for its GLP-1-based medications expected in the early 2030s. In 2026, Novo reported significant milestones in AI-assisted drug discovery facilitated by over 600 AI and digital professionals and more than 30 strategic AI partnerships. Although AI-driven drug development is still in early stages industry-wide and has yet to produce major breakthroughs, Novo executives remain optimistic. CEO Mike Doustdar noted that the adoption of AI will inevitably lead to disruptions within the company's workforce.
Industry Impact
AI becomes a portfolio-defense strategy
Pharma, healthcare AI, digital R&D
Overview
Novo Nordisk is using AI to speed drug discovery and diversify beyond its GLP-1 franchise as patent expiry approaches in the early 2030s. The company’s reported scale-up in AI talent and partnerships suggests AI is becoming a core R&D capability, not just an efficiency tool. For executives and investors, the key implication is that AI may help offset future revenue pressure, but workforce disruption and the limits of early-stage AI breakthroughs remain material execution risks.
Key Impact Points
AI is being used to strengthen the pipeline ahead of GLP-1 patent expiration.
More than 600 AI and digital professionals and 30+ partnerships indicate an organizational shift, not a pilot project.
The company expects AI adoption to disrupt parts of the workforce, signaling operating-model change.
Opportunities
AI-enabled pharma R&D opportunities
Pharma, healthcare AI, enterprise AI
The article supports a clear opportunity for AI tools that accelerate early discovery, trial design, and scientific workflows in pharmaceutical R&D. Novo Nordisk’s reported milestones point to demand for systems that prioritize targets, reduce trial setup time, and shorten clinical documentation cycles. The most realistic near-term opportunities are enterprise AI platforms, workflow automation, and specialized partnership models that help large drugmakers scale existing research processes rather than replace them. This is still a research-stage market, but it is already tied to operational efficiency and pipeline speed.
AI drug discovery workflow platform
Problem: Drug discovery and clinical development remain slow, resource-intensive, and dependent on large scientific teams.
Solution: Provide AI systems that help prioritize genes, analyze datasets, support trial site selection, and streamline clinical reporting.
Target Users: Pharmaceutical R&D teams, computational biology groups, clinical development teams, and AI/digital transformation leaders.
Business Value: Faster research cycles, better decision support, and lower time spent on repetitive scientific and trial-planning tasks.
Revenue Potential: Enterprise software contracts, services fees, and long-term partnership agreements with large pharma companies.
